This inventor holds 145 USPTO granted patents and 8 published patent applications, primarily in Therapeutic Polypeptides (CPC class C07K1-400). Top assignees: Genentech, Inc., Genetech, Inc., Schering Corporation. Active years: 2001-2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- South San Francisco, CA (US) (2003)
- San Fransisco, CA (US) (2007)
- San Francisco, CA (US) (2001 - 2012)
Company Filing History:
138 out of 3,301 
5 out of 98 
1 out of 1,829 
Years Active: 2001-2012
Areas of Expertise:
Title: J Christopher Grimaldi: A Pioneer in Therapeutic Polypeptide Inventions
Introduction:
J Christopher Grimaldi, a prominent inventor based in San Francisco, CA, has made significant contributions to the field of therapeutic polypeptides. With an impressive record of 144 patents, his innovative work has transformed the treatment landscape for degenerative cartilaginous disorders and various inflammatory diseases. This article delves into Grimaldi's latest patents, career highlights, notable collaborations, and his invaluable contributions to the scientific community.
Latest Patents:
Grimaldi's recent patents include "Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof" and "IL-17 receptor-like polypeptides and therapeutic uses thereof." These inventions revolve around the identification and utilization of novel polypeptides with sequence identity to IL-17 and IL-17 receptors. The corresponding nucleic acid sequences, vectors, and host cells provided in these patents offer promising avenues for treating degenerative cartilaginous disorders and various inflammatory diseases. Furthermore, the chimeric polypeptide molecules and antibodies described in these patents demonstrate Grimaldi's comprehensive approach to therapeutic development.
Career Highlights:
Throughout his remarkable career, J Christopher Grimaldi has played pivotal roles in renowned companies such as Genentech, Inc. and Schering Corporation. These companies have been at the forefront of medical innovation, consistently pushing boundaries and advancing patient care. Grimaldi's affiliation with such esteemed institutions underscores his expertise and determination to contribute to groundbreaking discoveries in the medical field.
Collaborations:
In his journey towards advancing therapeutic polypeptide inventions, Grimaldi has collaborated with esteemed colleagues, including William I Wood and Audrey Goddard. The synergy resulting from these partnerships has proven instrumental in the development of groundbreaking ideas and novel approaches to medical treatment. Grimaldi's collaborations with industry experts highlight his ability to foster creativity and harness new perspectives to address complex challenges.
Conclusion:
J Christopher Grimaldi's unwavering dedication to therapeutic polypeptide inventions has undoubtedly paved the way for innovative treatments in the fields of degenerative cartilaginous disorders and inflammatory diseases. His prolific patent portfolio and career highlights emphasize his role as a pioneer in revolutionizing medical approaches for improved patient care. Grimaldi's collaborations with esteemed colleagues further reinforce his commitment to fostering collaboration and driving transformative change within the scientific community. As the realm of therapeutic polypeptides continues to evolve, J Christopher Grimaldi's contributions are certain to leave a lasting impact, benefiting countless individuals in need of innovative medical solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile